Federal court suspends mifepristone mail delivery as restrictions expand
Federal appeals court blocks mifepristone mailing nationwide as Louisiana pursues expanded restrictions.
Event / Politics
Mifepristone Abortion Pill Legal Battle
Ongoing legal disputes over access to mifepristone, including Supreme Court stays and lower court rulings affecting FDA regulations on mail-order distribution and remote prescription of the medication.
5 reported locations
Daily activity
0 articles0 articles
2026-08-17 to 2026-11-14 · UTC publication dates
Coverage begins 2 May, 00:37 UTC
Follow the documented timeline or explore the related reporting.
What happened
US appeals court temporarily suspends telemedicine mifepristone access
On May 1st, a conservative appeals court temporarily suspended the ability to prescribe mifepristone via telemedicine and send it by mail across the country. This suspension was a major victory for anti-abortion activists. However, the suspension was quickly contested by pharmaceutical manufacturers and was itself suspended by the US Supreme Court.
One in four US abortion patients used telemedicine in early 2025
According to the Guttmacher Institute, a leading research organization on abortion access, one in four people who obtained an abortion with physician assistance in early 2025 did so via telemedicine.
Mifepristone used in medication abortion and miscarriage management
Mifepristone is used in combination with another pill (misoprostol) in medication abortions and also serves in the medical management of miscarriages. It has been employed for over 25 years and studies have demonstrated its safety and efficacy.
Mifepristone has been available via telemedicine prescription since 2021
Since 2021, mifepristone, an abortion pill used in the majority of medical abortions in the United States, has been available to be prescribed by telemedicine and sent by mail across the country.
FDA conducting safety review of mifepristone under Trump administration
The US Food and Drug Administration launched a re-evaluation of mifepristone's safety under the Trump administration at the request of anti-abortion advocates. This safety review could result in additional restrictions on the drug.
Supreme Court to decide on extending mifepristone telemedicine suspension
The conservative-majority Supreme Court must decide whether to extend a temporary suspension on telemedicine access to mifepristone. The current suspension expires at the end of the following Monday. The justices may also indicate whether they wish to take the case for full review.
Medication abortions account for majority of U.S. abortions
Medication abortions using mifepristone combined with misoprostol account for approximately 63% of U.S. abortions as of 2023, according to the Guttmacher Institute. The availability of these drugs has substantially blunted the impact of abortion bans imposed by Republican-led states since the 2022 Supreme Court ruling that overturned Roe v. Wade.
Supreme Court rejected mifepristone challenge in 2024, preserving drug access
In 2024, the Supreme Court unanimously rejected a challenge from anti-abortion doctors and medical groups who sought to restrict mifepristone access. The Court ruled that the plaintiffs lacked legal standing to sue the FDA. The decision preserved access to the drug but did not address broader questions about FDA authority or prevent states from filing new challenges.
Supreme Court issues administrative stay blocking 5th Circuit restrictions on mifepristone access
Justice Samuel Alito issued an administrative stay on Monday blocking a 5th U.S. Circuit Court of Appeals ruling that would have restricted access to the abortion pill mifepristone. The stay temporarily restores the FDA's current rules allowing mifepristone to be prescribed remotely and dispensed by mail or through pharmacies. The stay remains in effect until May 11 at 5 p.m. ET, giving the Court time to consider the case on the merits. Alito ordered Louisiana to file a response by May 7 at 5 p.m. ET.
FDA approved mifepristone in 2000 and expanded access over two decades
The FDA first approved mifepristone in 2000. The agency subsequently expanded access to the drug, including allowing its use through 10 weeks of pregnancy, permitting additional healthcare providers to prescribe it, and eventually removing in-person dispensing requirements. The FDA formally allowed telehealth prescriptions and mail delivery in 2023 after suspending enforcement of the in-person requirement during the COVID-19 pandemic.
5th Circuit Court of Appeals ruled to reinstate in-person dispensing requirements for mifepristone
On Friday, May 2, the 5th U.S. Circuit Court of Appeals ruled that the FDA's current policy allowing telehealth prescription and mail delivery of mifepristone undermined Louisiana state law. The three-judge panel, comprised of two Trump-appointed judges and one Bush-appointed judge, temporarily blocked telehealth provision of the pill while broader litigation continues. The ruling would have reinstated in-person dispensing requirements for the drug.
Some telehealth abortion providers prepared to shift to misoprostol-only regimens
Following the 5th Circuit's Friday ruling, some organizations providing abortion pills through telehealth had planned to switch to misoprostol-only treatment protocols. The Massachusetts Abortion Access Project and other groups were preparing to transition away from the mifepristone-misoprostol combination to continue serving patients in all 50 states.
Democratic-led states enacted laws protecting abortion pill prescribers
Some Democratic-led states have enacted laws designed to provide legal protection to healthcare providers who prescribe mifepristone and misoprostol via telehealth to patients residing in states with abortion bans. These laws aim to shield prescribers from liability under restrictive state laws.
Louisiana filed lawsuit challenging FDA's 2023 mifepristone regulatory changes
Louisiana Attorney General Liz Murrill brought a lawsuit in October arguing that the Biden administration violated the Administrative Procedure Act by making mifepristone permanently available by mail in 2021 and by removing in-person dispensing requirements. The state argued that the FDA's rules conflicted with Louisiana's abortion restrictions and exposed the state to costs tied to emergency care for women experiencing complications.
5th Circuit Court of Appeals blocks mailing of mifepristone prescriptions nationwide
The 5th U.S. Circuit Court of Appeals issued a unanimous ruling that reinstated a nationwide requirement for mifepristone to be obtained in person, effectively blocking the mailing of prescriptions for the abortion pill. The ruling affects all states, even those without abortion restrictions, and marks a substantial shift in abortion access policy following the 2022 overturning of Roe v. Wade.
Medication abortions account for over 60 percent of U.S. abortions in 2023
According to Guttmacher Institute research, medication abortions accounted for more than 60 percent of all abortions performed in the United States in 2023. This represents a significant increase in the prevalence of medication-based abortion methods following the overturning of Roe v. Wade, as conservative states have banned or severely limited access to clinic-based abortions.
Louisiana filed lawsuit challenging Biden-era mifepristone accessibility rule
Louisiana filed a lawsuit alleging that the Biden administration's rule allowing remote access to mifepristone undermines Louisiana's own abortion ban. A federal district court declined in April to restrict access to the drug until the FDA completed a safety review.
Biden administration ended in-person requirement for mifepristone in 2023
President Joe Biden's administration finalized rules in 2023 that eliminated the requirement for mifepristone to be obtained through in-person doctor's visits. This change followed the Supreme Court's 2022 decision overturning Roe v. Wade and allowed women to obtain the abortion pill through telehealth appointments since the COVID-19 pandemic.
FDA approved mifepristone as safe for ending early pregnancies in 2000
The FDA approved mifepristone in 2000 as a safe and effective method to end early pregnancies. It is typically used in combination with misoprostol, though it can be used alone with reduced effectiveness. The drug is considered to be overwhelmingly safe with fewer reported side effects than common medications like Viagra or penicillin.
Danco Laboratories files emergency appeal to Supreme Court to block mifepristone ruling
Danco Laboratories, the manufacturer of mifepristone, filed an emergency appeal with the U.S. Supreme Court on Saturday requesting an administrative stay to immediately pause the 5th Circuit's decision restricting mail access to the drug. The company argued that the ruling creates immediate confusion for patients with scheduled appointments and those seeking to obtain prescriptions already provided by providers.
Read the coverage
2 alternative perspectives
Mifepristone access narrows as courts and regulators tighten restrictions
Court blocks mifepristone mailing; federal reviews threaten access to medication used in most U.S. abortions.
Regulatory uncertainty clouds mifepristone's future as review timelines extend
Multiple regulatory reviews and court restrictions create uncertainty over mifepristone's approved status.
Two decades of FDA approval shaped mifepristone's regulatory path
FDA approval in 2000 and pandemic-era relaxed restrictions created mifepristone's modern regulatory framework.
Supreme Court's 2024 Mifepristone Decision Stands as Binding Precedent
Supreme Court's 2024 mifepristone precedent binds lower courts despite post-Roe legal changes.
Court blocks mifepristone mailing as FDA conducts new safety review
Appeals court blocks mifepristone mailing; Trump FDA launches new safety review amid state-level legal challenge.